Lab-Grown tumor 'Vessels' could predict who responds to immunotherapy
NCT ID NCT07343596
First seen Jan 19, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This study aims to see if a custom-made tumor culture system can predict how oral cavity cancer responds to the immunotherapy drug pembrolizumab before surgery. Twenty participants will provide a biopsy, receive pembrolizumab as standard care, and then have their tumor analyzed. Researchers will check if the lab model's predictions match the actual tumor response, with the goal of identifying biomarkers for personalized treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin - Madison
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab
What this could lead to
If successful, this could lead to a personalized test that predicts which oral cancer patients will benefit from immunotherapy before surgery.
What could go wrong
This is a very small, early-stage study (20 participants) focused on lab measurements, not treatment outcomes. The model may not reliably predict real-world responses.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.